Mudita Advisors LLP Has $6.79 Million Stock Holdings in Sotera Health (NASDAQ:SHC)

Mudita Advisors LLP grew its holdings in shares of Sotera Health (NASDAQ:SHC) by 5.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 406,329 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Sotera Health makes up 3.7% of Mudita Advisors LLP’s portfolio, making the stock its 10th largest position. Mudita Advisors LLP owned about 0.14% of Sotera Health worth $6,786,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FMR LLC raised its stake in shares of Sotera Health by 259.9% during the 3rd quarter. FMR LLC now owns 32,483 shares of the company’s stock worth $542,000 after purchasing an additional 23,457 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Sotera Health by 11.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 128,222 shares of the company’s stock valued at $2,141,000 after acquiring an additional 13,157 shares during the period. Cerity Partners LLC acquired a new position in shares of Sotera Health during the 3rd quarter worth about $1,489,000. Sessa Capital IM L.P. raised its holdings in shares of Sotera Health by 46.5% in the 3rd quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock valued at $105,220,000 after purchasing an additional 2,000,000 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Sotera Health by 18.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,348,917 shares of the company’s stock valued at $22,527,000 after purchasing an additional 208,914 shares during the last quarter. 91.03% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 16.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 55.12% of the stock is owned by company insiders.

Sotera Health Trading Down 2.6 %

SHC stock opened at $12.95 on Wednesday. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The company has a market capitalization of $3.67 billion, a PE ratio of 51.80 and a beta of 2.08. The company’s 50-day simple moving average is $15.46 and its 200 day simple moving average is $14.01. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. During the same period in the prior year, the business posted $0.18 earnings per share. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sotera Health will post 0.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on SHC shares. Citigroup lifted their target price on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Barclays upped their price objective on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research note on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Sotera Health presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.